Literature DB >> 24785562

Is dexamethasone an effective alternative to oral prednisone in the treatment of pediatric asthma exacerbations?

Jessica Sayre Meyer1, Jeffrey Riese, Eric Biondi.   

Abstract

BACKGROUND: A short course of systemic corticosteroids is an important therapy in the treatment of pediatric asthma exacerbations. Although a 5-day course of oral prednisone or prednisolone has become the most commonly used regimen, dexamethasone has also been used for a shorter duration (1-2 days) with potential for improvement in compliance and palatability. We reviewed the literature to determine if there is sufficient evidence that dexamethasone can be used as an effective alternative in the treatment of pediatric asthma exacerbations in the inpatient setting.
METHODS: A Medline search was conducted on the use of dexamethasone in the treatment of asthma exacerbations in children. The studies selected were clinical trials comparing the efficacy of dexamethasone with prednisone. Meta-analysis was performed examining physician revisitation rates and symptomatic return to baseline.
RESULTS: Six completed pediatric clinical trials met the inclusion criteria. All of the pediatric trials found that prednisone is not superior to dexamethasone in treating mild to moderate asthma exacerbations. Meta-analysis demonstrated homogeneity between the dexamethasone and prednisone groups when examining symptomatic return to baseline and unplanned physician revisits after the initial emergency department encounter. Some studies found potential additional benefits of dexamethasone, including improved compliance and less vomiting.
CONCLUSIONS: The current literature suggests that dexamethasone can be used as an effective alternative to prednisone in the treatment of mild to moderate acute asthma exacerbations in children, with the added benefits of improved compliance, palatability, and cost. However, more research is needed to examine the role of dexamethasone in hospitalized children.

Entities:  

Keywords:  asthma; dexamethasone

Mesh:

Substances:

Year:  2014        PMID: 24785562     DOI: 10.1542/hpeds.2013-0088

Source DB:  PubMed          Journal:  Hosp Pediatr        ISSN: 2154-1671


  6 in total

1.  Evaluation of the Efficacy of a Onetime Injectable Dexamethasone Administered Orally in the Pediatric Emergency Department for Asthma Exacerbation.

Authors:  Ashley McCallister; Tsz-Yin So; Josh Stewart
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Sep-Oct

2.  Ohio Pediatric Asthma Repository: Opportunities to Revise Care Practices to Decrease Time to Physiologic Readiness for Discharge.

Authors:  Jeffrey M Simmons; Jocelyn M Biagini Myers; Lisa J Martin; Carolyn M Kercsmar; Christine L Schuler; Valentina V Pilipenko; John W Kroner; Hua He; Stephen R Austin; Huyen-Tran Nguyen; Kristie R Ross; Karen S McCoy; Sherman J Alter; Samantha M Gunkelman; Pierre A Vauthy; Gurjit K Khurana Hershey
Journal:  Hosp Pediatr       Date:  2018-05-15

3.  Two regimens of dexamethasone versus prednisolone for acute exacerbations in asthmatic Egyptian children.

Authors:  Dalia A Elkharwili; Osama M Ibrahim; Gamal A Elazab; Shaymaa M Elrifaey
Journal:  Eur J Hosp Pharm       Date:  2018-11-10

4.  Observational study on the palatability and tolerability of oral prednisolone and oral dexamethasone in children in Saudi Arabia and the UK.

Authors:  Fahad Aljebab; Mofadhi Alanazi; Imti Choonara; Sharon Conroy
Journal:  Arch Dis Child       Date:  2017-07-22       Impact factor: 3.791

Review 5.  Guideline on management of the acute asthma attack in children by Italian Society of Pediatrics.

Authors:  Luciana Indinnimeo; Elena Chiappini; Michele Miraglia Del Giudice
Journal:  Ital J Pediatr       Date:  2018-04-06       Impact factor: 2.638

6.  Dexamethasone versus prednisone for children receiving asthma treatment in the paediatric inpatient population: protocol for a feasibility randomised controlled trial.

Authors:  Catherine M Pound; Jaime McDonald; Ken Tang; Gillian Seidman; Radha Jetty; Sarah Zaidi; Amy C Plint
Journal:  BMJ Open       Date:  2018-12-14       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.